A study of two drugs for advanced solid tumors
Part of Cancer clinical trials.
This trial tests two drugs combined—SHR-1501 and adbelizumab—for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have an advanced solid tumor (cancer that has spread or cannot be removed) that has gotten worse after standard treatment, or no standard treatment exists.
- You can take care of yourself and are up and about more than 50% of the day (ECOG 0 or 1).
- You have at least one tumor that can be measured on a scan.
- Your cancer has not spread to your brain causing symptoms, you do not have an autoimmune disease, and you are generally healthy enough for the trial.
- You have not had certain other treatments, infections, or medical conditions that would interfere with the study (your doctor will review all details).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SHR-1826, combined with other cancer treatments for people with advanced solid tumors that have not responded to prior therapy. The goal is to see if the combination is safe and effective.
This study tests an experimental drug combination for people with advanced solid tumors that have a specific protein called CLDN18.2. It aims to see if the combination works better than standard treatments.
This trial tests a new drug combination for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if adding SHR2554 tablets to other anticancer treatments can help control the disease.
This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
Hear when a new Patients With Advanced or Metastatic Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.